Compounds > proline

proline and Hematologic Diseases

proline has been researched along with Hematologic Diseases in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19902 (33.33)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Backus, LI; Belperio, PS; Mole, LA; Shahoumian, TA1
Clemente-Ricote, G; García-González, X; Giménez-Manzorro, Á; Ochoa-Palominos, A; Rodríguez-González, CG; Sanjurjo-Sáez, M1
Agata, N; Ebihara, T; Kawai, T; Lin, CY; Mukherjee, PM; Olsen, BR; Onji, M; Reichenberger, E; Saheki, Y; Senoo, M; Ueki, Y1
Bravo, EL; Fouad, FM; Vidt, DG1

Reviews

1 review(s) available for proline and Hematologic Diseases

ArticleYear
Drug therapy. Captopril.
    The New England journal of medicine, 1982, 01-28, Volume: 306, Issue:4

    Topics: Animals; Blood Pressure; Captopril; Drug Interactions; Heart Failure; Hematologic Diseases; Hemodynamics; Humans; Hypertension; Intestinal Absorption; Kidney; Pressoreceptors; Proline; Rats; Reflex; Renin-Angiotensin System

1982

Other Studies

5 other study(ies) available for proline and Hematologic Diseases

ArticleYear
Impact of provider type on hepatitis C outcomes with boceprevir-based and telaprevir-based regimens.
    Journal of clinical gastroenterology, 2015, Volume: 49, Issue:4

    Topics: Antiviral Agents; Cohort Studies; Female; Genotype; Health Personnel; Hematologic Diseases; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Oligopeptides; Proline; Retrospective Studies; Treatment Outcome; Veterans; Viral Load

2015
Boceprevir: serious haematological disorders.
    Prescrire international, 2014, Volume: 23, Issue:153

    Topics: Antiviral Agents; Drug Monitoring; Hematologic Diseases; Hepatitis C; Humans; Predictive Value of Tests; Proline; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome

2014
[Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice].
    Gastroenterologia y hepatologia, 2015, Volume: 38, Issue:10

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Emergency Service, Hospital; Female; Hematologic Diseases; Hepatitis C, Chronic; Hospitalization; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Remission Induction; Retrospective Studies; Ribavirin; Spain

2015
Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice.
    Cell, 2007, Jan-12, Volume: 128, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Animals; Arginine; Bone Marrow Cells; Bone Resorption; CD11b Antigen; Cell Differentiation; Cherubism; Disease Models, Animal; Hematologic Diseases; Homozygote; Inflammation; Intracellular Signaling Peptides and Proteins; Lymph Nodes; Macrophage Colony-Stimulating Factor; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Myeloid Cells; Osteoclasts; Phosphorylation; Proline; Protein-Tyrosine Kinases; RANK Ligand; Spleen; Syk Kinase; Tumor Necrosis Factor-alpha

2007
Captopril: benefits and risks in severe hypertension.
    Lancet (London, England), 1980, Jul-19, Volume: 2, Issue:8186

    Topics: Animals; Captopril; Diuretics; Dogs; Drug Therapy, Combination; Hematologic Diseases; Humans; Hypertension; Kidney; Mice; Proline; Rats

1980